Erectile Dysfunction Clinical Trial
Official title:
Low-Intensity Extracorporeal Shock Wave Therapy for the Treatment of Vasculogenic Erectile Dysfunction
This study aims to evaluate the safety and efficacy of low-intensity extracorporeal shock wave therapy utilizing the Dornier Aries in the treatment of erectile dysfunction of vasculogenic origin.
An increasing number of men are suffering from the effects of Erectile Dysfunction (ED) each
year. The development of oral therapies (phosphodiesterase 5 inhibitors) has been successful
for many with the disease. However, these drugs may be contraindicated in patients with
cardiovascular risk factors (which are often predecessors to developing ED) and are often
ineffective in patients with other comorbid conditions, such as diabetes mellitus. The main
objective of this study is to determine the safety and efficacy of low-intensity
extracorporeal shock wave therapy using the Dornier Aries in the treatment of erectile
dysfunction of vasculogenic origin.
This protocol allows for treatment of 23 men with 21-75 years of age with vasculogenic
erectile dysfunction of at least 6 months' duration with low intensity extracorporeal shock
wave therapy utilizing the Dornier Aries device.
This protocol includes the application of 5000 shockwaves per session in 5 treatment areas
with 1000 SW each at energy level 4-5 (energy flux density (0.051-0.062 mJ/mm²), while
moving the applicator along the penile shaft within the treatment areas. The maximum energy
applied during this treatment would be 23.35J.
Conversely, the treatment protocol described within is designed to actually restore penile
function as a disease-modifying therapy, and is not expected to require a maintenance
regimen or continued treatments, as previous studies have demonstrated retained benefits at
six months after the end of treatments.
Dornier MedTech hired an independent party to monitor data and perform internal audits to
ensure the precision, quality, and integrity of the data collected. The investigator(s)
agrees to permit access to study records, source data, and source documents for this
purpose.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05366504 -
LiST Plus PRP Injection Therapy vs LiST Monotherapy for ED Treatment
|
Phase 2/Phase 3 | |
| Recruiting |
NCT02745808 -
Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
| Recruiting |
NCT02573805 -
the Diagnostic Value of Rigiscan Test (Nocturnal Penile Tumescence and Rigidity, NPTR) in Chinese Males
|
N/A | |
| Withdrawn |
NCT01967251 -
Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction
|
Phase 2 | |
| Withdrawn |
NCT02579148 -
Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
| Recruiting |
NCT02225548 -
Sagene 2014 - Parkinson's Disease and Erectile Dysfunction
|
Phase 4 | |
| Completed |
NCT02587988 -
Trial to Evaluate the Efficacy and Safety of HCP1302
|
Phase 3 | |
| Completed |
NCT02945462 -
Bone Marrow Mesenchymal Stem Cells in Erectile Dysfunction (ED)
|
Phase 1 | |
| Completed |
NCT01937871 -
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)
|
Phase 3 | |
| Completed |
NCT01698684 -
Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction
|
Phase 4 | |
| Not yet recruiting |
NCT01321489 -
A Study to Evaluate a Possible Superiority Expressed by the Faster Onset of Action and the Efficacy and Safety of Sildenafil Citrate 20mg Sublingual Tablet in the Treatment of Erectile Dysfunction of Different Etiologies
|
Phase 3 | |
| Completed |
NCT01230541 -
Effect of Udenafil on Spermatogenesis
|
Phase 1 | |
| Terminated |
NCT01262833 -
Pudendal Assessment in Erectile Dysfunction
|
N/A | |
| Completed |
NCT02226237 -
Effectiveness of Physiotherapy to Treat the Urinary Incontinence and Erectile Dysfunction Post Retropubic Prostatectomy
|
N/A | |
| Completed |
NCT01037244 -
Treatment of Erectile Dysfunction I
|
Phase 3 | |
| Completed |
NCT01037218 -
Treatment of Erectile Dysfunction II
|
Phase 3 | |
| Recruiting |
NCT00313898 -
Effect of Sildenafil on Quality of Sexual Life in Mild to Normally Sexually Functioning Males
|
Phase 4 | |
| Completed |
NCT00421083 -
Efficacy and Safety of Tadalafil in Subjects With Erectile Dysfunction Caused by Spinal Cord Injury
|
Phase 3 | |
| Completed |
NCT00667979 -
Evaluating the Efficacy of Vardenafil in Subjects With Erectile Dysfunction (ED) Administered 12, 18 or 24 Hours Prior to Intercourse
|
Phase 4 | |
| Completed |
NCT00663728 -
Assessment of Duration of Erection With Vardenafil 10 mg
|
Phase 4 |